Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Syntimmune
Fierce Pharma
Syntimmune shareholders win again over AZ, this time for $181M
A Delaware judge has sided with Syntimmune shareholders over AstraZeneca, granting a $181 million award on top of a $130 million decision last year.
Kevin Dunleavy
Jun 12, 2025 11:40am
Frontier launches with biotech vet CEO—Chutes & Ladders
Jun 28, 2019 9:30am
After being bought by Alexion, Syntimmune's CEO joins MorphoSys
Jun 25, 2019 7:54am
Canaan-backed Comet uncloaks with $28.5M and De Graaf as CEO
Jun 19, 2019 7:00am
Alexion adds to pipeline with $1.2B Syntimmune buy
Sep 26, 2018 9:15am
Chutes & Ladders—Gilead director joins Nimbus to lead discovery
Jul 13, 2018 8:30am
